Yet another bispecific, humanized IgG1 antibody that may be less than investigation is zenocutuzumab (MCLA-128), which acts by way of two independent mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by way of ADCC. MCLA-128 capabilities through a ‘dock and block’ mechanism whereby one particular arm https://www.directivepublications.org/journal-of-clinical-breast-cancer/